All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Every GLP-1 Drug Ranked by Effectiveness (2025)

Clinical comparison of all GLP-1 drugs ranked by weight loss effectiveness. Tirzepatide leads at 22.5%, followed by semaglutide at 14.9%. Expert...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Every GLP-1 Drug Ranked by Effectiveness (2025) custom 2026 header image for Provider Comparisons
Custom header image for Every GLP-1 Drug Ranked by Effectiveness (2025), Provider Comparisons, and better treatment decision-making.
In This Article

This article is part of our Provider Comparisons collection. See also: GLP-1 Guides | Peptide Guides

Search and AI answer brief

Practical answer: Every GLP-1 Drug Ranked by Effectiveness (2025)

Clinical comparison of all GLP-1 drugs ranked by weight loss effectiveness. Tirzepatide leads at 22.5%, followed by semaglutide at 14.9%. Expert...

Short answer

Clinical comparison of all GLP-1 drugs ranked by weight loss effectiveness. Tirzepatide leads at 22.5%, followed by semaglutide at 14.9%. Expert...

Search intent

This page answers a specific Provider Comparisons question rather than a generic overview.

What to verify

semaglutide, tirzepatide, cash price and coverage terms, safety and contraindications

How to use it

Use this information to prepare sharper questions for a licensed provider.

There are several GLP-1 based medications, and they are not interchangeable. They differ in strength, dosing, approved uses, and cost. This guide ranks the main options and, more importantly, explains why the "best" one depends on your goal.

Quick answer

For weight loss, tirzepatide (a dual GIP/GLP-1 agonist sold as Mounjaro for diabetes and Zepbound for weight management) generally produced the largest average weight loss in clinical trials, ahead of semaglutide (Ozempic/Wegovy). Semaglutide is the next strongest and is extremely well established. Older agents like liraglutide, dulaglutide, and exenatide are effective but generally produce less weight loss. The single "best" drug depends on whether your priority is weight loss, diabetes control, dosing convenience, tolerability, or cost.

How the GLP-1 drugs compare

The major FDA-approved options fall into a rough hierarchy for weight loss, based on trial results for the drug classes studied:

Medication (brand)TypePrimary use(s)Relative weight-loss strength
Tirzepatide (Mounjaro, Zepbound)Dual GIP/GLP-1Diabetes; weight managementHighest in trials
Semaglutide (Ozempic, Wegovy, Rybelsus)GLP-1Diabetes; weight managementHigh
Dulaglutide (Trulicity)GLP-1DiabetesModerate
Liraglutide (Victoza, Saxenda)GLP-1Diabetes; weight managementModerate, less than semaglutide
Exenatide (Byetta, Bydureon)GLP-1DiabetesLower / older

Note that tirzepatide is technically a dual agonist (it acts on two receptors, GIP and GLP-1), which is part of why it is so potent, while the others act on GLP-1 alone. They are different molecules, not versions of the same drug.

1. Tirzepatide (Mounjaro / Zepbound)

For weight loss, tirzepatide tops the list. In the trials of this drug class (the SURMOUNT program), it produced the largest average weight loss of the approved options. Its dual mechanism, acting on both GIP and GLP-1 pathways, is thought to underlie its strength. It is dosed once weekly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management.

Not sure which GLP-1 is right for you?

Take a 2-minute assessment and get a personalized recommendation after licensed provider review.

Take the Assessment →

2. Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide is the most famous GLP-1 and a very strong performer. In its weight-management trials (the STEP program), it produced substantial weight loss, generally less than tirzepatide but well ahead of older agents. It is dosed once weekly as an injection (Ozempic for diabetes, Wegovy for weight management), with an oral daily tablet form (Rybelsus) for diabetes. Its long track record and flexibility make it a default for many people.

3. Dulaglutide (Trulicity)

Dulaglutide is a once-weekly GLP-1 used for type 2 diabetes. It is effective for blood sugar with a moderate weight effect, less than semaglutide or tirzepatide. It is a solid diabetes option but not a first pick when maximum weight loss is the goal.

4. Liraglutide (Victoza / Saxenda)

Liraglutide is an older GLP-1, notable for being dosed daily rather than weekly. Victoza is for diabetes and Saxenda for weight management. It produces meaningful but generally smaller weight loss than semaglutide, and the daily injection is less convenient than the weekly options.

5. Exenatide (Byetta / Bydureon)

Exenatide is one of the earlier GLP-1 medications, used for type 2 diabetes. It is effective for blood sugar but generally produces less weight loss than the newer agents and is less commonly chosen for weight goals today.

Which GLP-1 is best for you?

The ranking above is for weight loss, but "best" is personal:

  • Maximum weight loss: tirzepatide leads, with semaglutide close behind.
  • Diabetes with weight benefit: tirzepatide or semaglutide are strong; dulaglutide is a good weekly diabetes option.
  • Oral preference: Rybelsus (oral semaglutide) is the main oral option, for diabetes.
  • Tolerability: all share GI side effects; individual response varies, so the "best tolerated" one differs by person.
  • Cost and access: prices and coverage differ, and this often shapes the real-world choice as much as potency.

How to choose with a clinician

The right GLP-1 is a decision to make with a licensed prescriber who weighs your goals, health history, tolerability, and budget. For people focused on weight management, FormBlends offers compounded semaglutide through licensed prescribers and a provider comparison tool to compare options side by side.

Frequently asked questions

Which GLP-1 drug is best for weight loss? Tirzepatide generally produced the largest average weight loss in trials, with semaglutide next. Older agents produce less.

What is the strongest GLP-1? For weight loss, tirzepatide (a dual GIP/GLP-1 agonist) led the trials of its class, ahead of semaglutide.

Are all GLP-1 drugs the same? No. They are different molecules with different strengths, dosing, and approved uses. Tirzepatide is a dual agonist; the others act on GLP-1 alone.

Which GLP-1 is best for diabetes? Tirzepatide and semaglutide are strong for diabetes with weight benefits; dulaglutide is a solid weekly diabetes option. Your prescriber decides based on your situation.

Is there an oral GLP-1? Yes. Rybelsus is oral semaglutide, approved for type 2 diabetes.

Which has the fewest side effects? All share gastrointestinal side effects, and individual tolerability varies, so there is no universal answer. Slow titration helps with any of them.

How do I choose? Decide with a licensed prescriber based on your goal (weight vs diabetes), tolerability, dosing preference, and cost.

Sources

  • New England Journal of Medicine, SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide) obesity trials - https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  • National Institute of Diabetes and Digestive and Kidney Diseases: Prescription Medications to Treat Overweight and Obesity - https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

Talk to a licensed provider

Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.

Start the assessment →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-05-31T23:50:00Z
FormBlends review
FormBlends official source
Official source
Mounjaro evidence source
Official source
Ozempic evidence source
Official source
Saxenda evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-05-31T23:50:00Z.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Every GLP-1 Drug Ranked by Effectiveness (2025), FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

Every GLP-1 Drug Ranked by Effectiveness (2025) should help you decide which option deserves a clinical review, not force a one-size answer.

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Clinical comparison of all GLP-1 drugs ranked by weight loss effectiveness. Tirzepatide leads at 22.5%, followed by semaglutide at 14.9%. Expert analysis of. Treat "Every GLP-1 Drug Ranked by Effectiveness (2025)" as a way to pressure-test a decision before money, medication, or provider access is involved. The article ties semaglutide, tirzepatide, provider access back to patient education and clinical context. It belongs in a comparison page where the details that matter most are access, cost, clinical fit, and what a licensed clinician should confirm. Because this article has 10 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Keep the final call tied to your own labs, history, medications, and clinician guidance.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Every GLP

For this provider comparisons page, the 2026 refresh focuses on semaglutide, tirzepatide, cash-pay pricing, safety signals, all, glp1 so the article stays close to the question behind "Every GLP".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Every GLP from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Every GLP custom 2026 image for provider comparisons on FormBlends

Custom 2026 image for Every GLP, provider comparisons, and better treatment decision-making.

Image description: Unique image for this page covering Every GLP, provider comparisons, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Disclosure: FormBlends is one of the providers discussed in this article. Our editorial team independently researches and verifies all pricing and claims. Pricing was last verified in March 2026. Read our editorial policy.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.